PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma

Erstveröffentlichung

2023

Authors

Klümper, Niklas

Wüst, Lennert

Saal, Jonas

Ralser, Damian J.

Zarbl, Romina

et al.

Wissenschaftlicher Artikel

Published in

OncoImmunology ; 12 (2023), 1. - Art.-Nr. 2267744. - ISSN 2162-4011. - eISSN 2162-402X

Link to publication

https://dx.doi.org/10.1080/2162402X.2023.2267744

Institutions

UKU. Klinik für Urologie und Kinderurologie

Subject headings

[Free subject headings]: biomarker | bladder cancer | CD274 | DNA methylation | immune checkpoint blockade | immunotherapy | metastatic urothelial carcinoma | PD-L1 | promoter methylation | CISPLATIN-INELIGIBLE PATIENTS | T-CELLS | PROSTATE-CANCER | SINGLE-ARM | BIOMARKERS | PEMBROLIZUMAB | ATEZOLIZUMAB | MULTICENTER | KEYNOTE-052
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record